[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"postherpetic-neuralgia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:postherpetic-neuralgia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,42,80,103,127,150,171,198,224,249,270,290],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100614143","phase-2-y-4-to-treat-the-postherpetic-neuralgia-100614143",false,"NCT07275762","Y-4 to Treat the Postherpetic Neuralgia","A Multicenter, Randomized, Double-blind, Double-dummy, Parallel-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of Y-4 Tablets in Chinese Patients With Postherpetic Neuralgia, Compared With Pregabalin Capsules","Inclusion Criteria:\n\n\\- 1. Able to understand and voluntarily sign the informed consent form. 2. Age ≥ 18 years, any gender. 3. Diagnosed with PHN, meaning pain persists for more than one month after the acute shingles rash has healed.\n\n4\\. VAS score in SF-MPQ ≥ 40 mm of the last 24 hours during screening.\n\nExclusion Criteria:\n\n* 1\\. Known previous allergy to the investigational products, rescue medication ingredients, other chemically similar drugs, or excipients.\n\n  2\\. During screening, individuals who have been clearly diagnosed with peripheral neuropathy or pain unrelated to PHN (including but not limited to those caused by cerebrovascular disease, Guillain-Barré syndrome, cervical or lumbar spine disorders, osteoarticular or tendon lesions, chronic kidney disease or uremia, thyroid disease, intracranial tumors, trauma, etc.) and are judged by the investigator to potentially confound the assessment of PHN.\n\n  3\\. During screen, suffer from a systemic disease that, in the opinion of the investigator, may affect the patient's participation in the study or affect the evaluation of the efficacy of PHN, including but not limited to:\n  1. Severe cardiopulmonary diseases, such as unstable angina, myocardial infarction, severe arrhythmia within 6 months prior to screening, NYHA cardiac function classification of grade III\\~IV at screening, hypertension (systolic blood pressure \\> 160 mmHg or diastolic blood pressure \\> 100 mmHg at screening), recurrent asthma attacks, etc.;\n  2. Chronic digestive diseases, such as liver fibrosis, chronic active hepatitis, peptic ulcer, etc.;\n  3. Neuropsychiatric disorders, including epilepsy, recurrent dizziness or headache, cognitive impairment; Cerebrovascular disease (such as cerebral infarction) or recurrent transient ischemic attack within 6 months prior to screening;\n  4. History of malignant tumors within 5 years prior to screening (excluding cured basal cell carcinoma of the skin, carcinoma in situ and papillary thyroid carcinoma);\n  5. Presence of active infection, which, in the opinion of the investigator, is not suitable for entry into this study;\n  6. Diabetic patients with poor glycemic control (peritoneal venous blood glucose ≥11mmol\u002FL at screening);\n  7. Suffering from immunocompromised diseases, such as systemic lupus erythematosus, acquired immunodeficiency syndrome, immunosuppressant therapy for autoimmune diseases.\n\n  4\\. During screening, situations may exist that investigators believe could affect pain assessment, such as if the affected skin area has a skin condition that may influence sensation.\n\n  5\\. Previously received nerve destruction for PHN, or underwent minimally invasive interventions (such as nerve blocks or neurostimulation), physical therapy (such as red light therapy), or traditional Chinese external treatments (such as acupuncture) within one week prior to screening.\n\n  6\\. Use prohibited drugs within the first 5 half-lives, or change the restricted drug dosage within the first 14 days.\n\n  7\\. Severe hematological, hepatatological, and renal function abnormalities at the time of screening, which meet any of the following laboratory test results: 1) Hematology: neutrophil count \\\u003C 1.5×109\u002FL, or platelet \\\u003C 90×109\u002FL, or hemoglobin \\\u003C100g\u002FL; 2) Liver function: ALT or AST \\> 2.5 times ULN; or TBIL \\> 1.5 times ULN; 3) Renal function: CrCL\\\u003C60 mL\u002Fmin\u002F1.73 m2 (calculated based on Cockroft-Gault formula a); 4) Creatine kinase \\>2-fold ULN.\n\n  8\\. Participants already diagnosed with sleep apnea, or those with severe snoring and daytime sleepiness, as well as intermittent hypoxia.\n\n  9\\. Participants with a history of suicidal behavior, or those assessed to have suicidal tendencies using the Columbia-Suicide Severity Rating Scale (C-SSRS).\n\n  10.Hepatitis B surface antigen (HBsAg) positive and HBV-DNA titer \\>lower limit of reference value, or hepatitis C virus antibody (HCV-Ab) positive and HCV-DNA titer \\>lower limit of reference value, or human immunodeficiency virus antibody (HIV-Ab) positive, or serum Treponema pallidum-specific antibodies (TP-Ab) positiv eand rapid plasma reagin\u002Ftoluidine red unheated serum test (RPR or TRUST) positive at screening.\n\n  11\\. Known drug abuse, or history of alcohol abuse within 1 year prior to screening, i.e., drinking more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of spirits with 40% alcohol or 150 mL of wine).\n\n  12\\. Pregnant or lactating females. 13.Male (or their partner) or female subjects have a fertility plan during the whole study period and within 1 month after the end of the study or are unwilling to take one or more non-drug contraceptive measures (such as condoms, intrauterine devices, etc.) during the study period.\n\n  14.Prior participation in any other clinical study of any other drug within 30 days prior to screening.\n\n  15.Engaging in high-altitude work, driving motor vehicles, or operating heavy machinery with associated risks during the study period.\n\n  16.Other conditions that are considered unsuitable by the investigator to participate in this clinical study.","ALL","18 Years",{"count":19,"type":20},160,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The goal of this clinical trial is to assess the efficacy and safety of Y-4 in patients with postherpetic neuralgia(PHN).\n\nThe main questions it aims to answer are: The efficacy and safety of Y-4 to treat PHN compared with pregabalin.\n\nResearchers will analyze data from different groups, includes Y-4 group and pregabalin group , to see efficacy of Y-4 and If drug Y-4 is safe and tolerate in the patients with PHN.\n\nParticipants will :\n\n* Take Y-4 (1w titration period: 75 mg pregabalin +18.75 mg riluzole, 12w fixed dose period: 150 mg pregabalin +37.5 mg riluzole, 1w drug withdraw period: 1w titration period: 75 mg pregabalin +18.75 mg riluzole) or pregabalin(75 mg for 1w titration period , 150 mg for 12w fixed dose period ,75 mg for 1w drug withdraw period) twice a day for 14 weeks after run-in period (placebo) lasting for 1 week.\n* Visit the hospital according to the follow-up schedule agreed upon with your doctor. contact the research staff as soon as possible to reschedule when unable to attend the scheduled study visit.\n* Use investigational products as directed by the doctor and undergo the related treatment.\n* Inform their investigators of any changes in their health, including any side effects or symptoms, whether or not they believe these changes are related to the trial medication, as well as any new medications they are using or wish to use, or any changes in the dosage of medications they have already taking.\n* Use reliable contraceptive methods , such as abstinence, intrauterine devices, double barrier methods (e.g., condom with spermicide or condom with a diaphragm containing spermicide), contraceptive implants, or oral contraceptives (except if the partner is infertile) during the study period and within one month after the study is completed.\n* Must inform investigators immediately if they or their partner become pregnant during the study.\n* Be sure to inform other doctors being consultant that you are participating in this clinical study.\n* Restrict medication use and treatment during the study.",[26,27,28],"Postherpetic Neuralgia","Y-4","Pregabalin","RECRUITING","2026-05-09",{"date":32,"type":33},"2026-05-13","ACTUAL",{"date":35,"type":33},"2026-02-02",{"date":37,"type":20},"2026-11-30",{"name":39,"class":40},"Neurodawn Pharmaceutical Co., Ltd.","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":4},"100636768","efficacy-and-safety-of-high-concentration-35-kda-hyaluronan-gel-for-herpes-zoster-associated-pain-100636768","NCT07569978","Efficacy and Safety of High-Concentration 35 kDa Hyaluronan Gel for Herpes Zoster-Associated Pain","A Prospective, Single-Arm, Open-Label Pilot Clinical Study to Evaluate the Efficacy and Safety of Topical 10% High-Concentration 35 kDa Hyaluronan (HA35) Gel in Subjects With Herpes Zoster-Associated Pain","HA35-HZ","Inclusion Criteria:\n\n* Age 18-85 years, male or female\n* Clinically diagnosed with herpes zoster-associated pain (acute ZAP or PHN)\n* Baseline pain NRS score ≥5\n* Ability to understand and complete NRS assessments\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Acute bacterial skin infection at the application site\n* Use of topical analgesics or antiviral therapy within 24 hours\n* Systemic analgesic use within 6 hours\n* Known hypersensitivity to hyaluronan or gel components\n* Pregnant or lactating women\n* Severe systemic disease or malignant tumor","85 Years",{"count":52,"type":20},30,[54],"NA","This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of topical 10% high-concentration 35 kDa hyaluronan (HA35) gel in subjects with herpes zoster-associated pain (ZAP). Eligible participants will receive a single topical application of the study gel. The primary objective is to assess rapid pain reduction within 2 minutes and 24hours after application. Secondary objectives include evaluation of analgesic duration, local tolerability, erythema improvement, and overall safety throughout the observation period. This is a minimal-risk, non-pharmacological supportive care intervention.",[57,58,26,59,60],"Herpes Zoster","Zoster-Associated Pain","Neuropathic Pain","Acute Pain",[62,63,64,65,57,66,26,59,67,68,69],"Hyaluronan","35 kDa Hyaluronan","HA35","Topical Gel","Zoster Pain","Analgesia","Non-pharmacological Intervention","Pilot Clinical Study","NOT_YET_RECRUITING","2026-05-05",{"date":73,"type":33},"2026-05-08",{"date":75,"type":20},"2026-05-01",{"date":77,"type":20},"2026-07-10",{"name":79,"class":40},"Nakhia Impex LLC",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":21,"phases":89,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":41},"100620759","the-analgesic-efficacy-and-safety-of-venlafaxine-for-prevention-of-postherpetic-neuralgia-in-patients-with-acute-herpes-zoster-100620759","NCT07361796","The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster","The Analgesic Efficacy and Safety of Oral Medications (Venlafaxine) for Prevention of Postherpetic Neuralgia in Acute Herpes Zoster","Inclusion Criteria:\n\n* 1\\. Ages more than 18 years;\n* 2\\. Patients with onset of HZ rash less than 30 days;\n* 3\\. Experiencing moderate to severe HZ pain with an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0 = no pain, 10 = worst possible pain);\n* 4\\. Aspartate aminotransferase and alanine aminotransferase levels less than twice the upper limit of normal;\n* 5\\. Estimated glomerular filtration rate of 30 mL\u002Fmin per 1.73 m2 or higher;\n* 6\\. Willing to sign the informed consent form and possessing sufficient cognitive and language abilities to comply with all the study requirements.\n\nExclusion Criteria:\n\n* 1\\. HZ with head, neck, ocular, mucous membrane, cranial nerve, or central nervous system involvement or generalized HZ;\n* 2.Known hypersensitivity to venlafaxine;\n* 3.History of major depressive disorder requiring antidepressant therapy;\n* 4.History of systemic immune diseases, organ transplantation, or cancers;\n* 5.Pregnancy or lactation;\n* 6.Presence of acute or chronic pain disorders other than HZ.",{"count":88,"type":20},832,[54],"Postherpetic neuralgia (PHN) is the most common complication of herpes zoster (HZ) and represents a major clinical challenge due to its chronicity and impact on quality of life. Current treatments for acute HZ pain have limited efficacy in preventing PHN, highlighting the need for effective preventive strategies targeting early pathophysiological mechanisms. Venlafaxine as a plausible and clinically relevant candidate for early intervention to prevent the transition from acute HZ pain to PHN.",[57,92,26],"Pain","2026-03-23",{"date":95,"type":33},"2026-03-27",{"date":97,"type":33},"2025-12-15",{"date":99,"type":20},"2027-12-31",{"name":101,"class":102},"Beijing Tiantan Hospital","OTHER",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":114,"conditions":115,"keywords":116,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":41},"100623746","erector-spinae-plane-block-versus-transcutaneous-radiofrequency-in-postherpetic-neuralgia-100623746","NCT07400640","Erector Spinae Plane Block Versus Transcutaneous Radiofrequency in Postherpetic Neuralgia","Which Is More Effective in the Treatment of Postherpetic Neuralgia: Erector Spinae Plane Block or Transcutaneous Radiofrequency?","Inclusion Criteria:\n\nDiagnosis of postherpetic neuralgia involving cervical, thoracic, or lumbar regions\n\nAge between 18 and 80 years\n\nPersistent pain despite conservative treatment\n\nBaseline VAS score \\> 5\n\nExclusion Criteria:\n\nOphthalmic or extremity postherpetic neuralgia\n\nAllergy to local anesthetics\n\nPregnancy\n\nCoagulopathy or use of antiplatelet therapy\n\nCognitive impairment preventing informed consent","80 Years",{"count":112,"type":20},50,"OBSERVATIONAL","This observational study aims to compare the effectiveness of ultrasound-guided erector spinae plane (ESP) block and transcutaneous radiofrequency (RF) treatment in patients with postherpetic neuralgia. Pain intensity and neuropathic pain characteristics will be evaluated using the Visual Analog Scale (VAS) and the Self-Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) score.",[26,59,57],[117],"postherpetic neuralgia, esp block, transcutaneous rf","2026-02-23",{"date":120,"type":33},"2026-02-25",{"date":122,"type":33},"2025-06-01",{"date":124,"type":20},"2026-10-01",{"name":126,"class":102},"Diskapi Teaching and Research Hospital",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":135,"conditions":136,"keywords":139,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":41},"100622950","efficacy-of-transcutaneous-pulsed-radiofrequency-in-postherpetic-neuralgia-100622950","NCT07390279","Efficacy of Transcutaneous Pulsed Radiofrequency in Postherpetic Neuralgia","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of postherpetic neuralgia (PHN)\n* No invasive or noninvasive treatment related to PHN (e.g., capsaicin, lidocaine patches) within the past 3 months\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Patients with a cardiac pacemaker\n* Known allergy to transcutaneous electrode pads\n* Active skin infection at the pad application site\n* Presence of a metallic implant in the treatment area\n* Circulatory disorders or skin lesions at the treatment site\n* Inability to maintain appropriate positioning\n* Inability to communicate effectively\n* Presence of psychosis or progressive neurological deficits\n* Pregnancy",{"count":134,"type":20},35,"Postherpetic neuralgia (PHN) is a chronic pain syndrome that may be resistant to treatment and can lead to physical and social disability as well as psychological disturbances, persisting for years in some patients. Varicella zoster virus remains latent in the sensory neurons of individuals who have previously had chickenpox. Reactivation of the latent virus results in herpes zoster. Herpes zoster typically begins with dermatomal pain, followed within a few days by the development of characteristic dermatomal skin rashes. These cutaneous lesions usually resolve within 2-4 weeks; however, pain may persist even after the rash has healed.\n\nThere is variability in the literature regarding the definition of PHN. The development of PHN is associated with increased central neuronal sensitization, reduced inhibitory neuronal function, inflammation and nerve injury in the peripheral nervous system, and abnormal neural transmission following nerve damage. PHN is the most common complication of herpes zoster and occurs in approximately 9-19% of affected patients. Its incidence increases with age, occurring in about 2% of patients under 50 years of age, approximately 20% of those over 50 years, and nearly 35% of patients over 80 years of age.\n\nVarious treatment options are available for the management of PHN-related pain, including pharmacological and interventional approaches. Systemic agents include tricyclic antidepressants, calcium channel alpha-2-delta ligands, serotonin-norepinephrine reuptake inhibitors, and opioids, while topical treatments include lidocaine and capsaicin. Interventional treatment options for PHN include epidural and intrathecal injections, sympathetic nerve blocks, erector spinae plane block, subcutaneous injections, and spinal cord stimulation.",[26,137,138],"Chronic Pain","Neuropathy",[140],"postherpetic neuralgia","2026-01-28",{"date":143,"type":33},"2026-02-05",{"date":145,"type":20},"2026-02-01",{"date":147,"type":20},"2026-08-03",{"name":149,"class":102},"Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":110,"enrollmentInfo":158,"targetDuration":4,"studyType":21,"phases":160,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":167,"leadSponsor":169,"locationsCount":41},"100620048","brain-stimulation-for-postherpetic-neuralgia-a-randomized-sham-controlled-trial-100620048","NCT07352553","Brain Stimulation for Postherpetic Neuralgia: A Randomized Sham-Controlled Trial","Non-invasive Brain Stimulation for Postherpetic Neuralgia: A Prospective, Randomized, Sham-Controlled Study","PHN","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Diagnosis of postherpetic neuralgia (PHN) with disease duration ≥ 3 months.\n* NRS pain score ≥ 4.\n* Willing to receive the intervention and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Contraindications to electrical stimulation (e.g., intracranial metal implants, cardiac pacemaker).\n* History of epilepsy, severe psychiatric disorder, or cognitive impairment.\n* Pregnant or breastfeeding women.\n* Unable to comply with the intervention procedures and follow-up assessments.",{"count":159,"type":20},94,[54],"Pharmacotherapy is the cornerstone of Postherpetic Neuralgia (PHN) management. First-line treatments for PHN include antiviral agents (e.g., acyclovir, valacyclovir, famciclovir, and brivudine), centrally acting antiepileptic drugs (pregabalin and gabapentin), antidepressants (duloxetine and venlafaxine), and peripherally acting sodium-channel blockers (lidocaine patches).\n\nIn recent years, substantial progress has been made in the prevention and treatment of PHN, including early and active antiviral therapy (acyclovir, valacyclovir, famciclovir, brivudine, etc.), analgesic therapy (calcium-channel modulators such as pregabalin and gabapentin; tricyclic antidepressants such as amitriptyline; and opioid analgesics), interventional procedures (e.g., radiofrequency modulation and spinal cord stimulation), and vaccination. Nevertheless, clinical outcomes remain unsatisfactory, with the incidence of refractory PHN still exceeding 50%. Adverse effects associated with certain first- and second-line medications (such as antidepressants and anticonvulsants), as well as the potential risk of opioid dependence, markedly reduce treatment adherence. This situation has compelled clinicians to continually seek new and effective therapeutic approaches for PHN.\n\nNon-invasive transcranial stimulation, as an emerging noninvasive neuromodulation technique, enables targeted modulation of deep brain structures. Animal studies have demonstrated that it can noninvasively regulate neuronal firing in deep regions and induce long-term plasticity, while offering relatively high spatial selectivity and tissue penetration. These features suggest broad clinical potential in chronic pain and affective disorders.",[26],"2026-01-11",{"date":165,"type":33},"2026-01-20",{"date":165,"type":20},{"date":168,"type":20},"2026-07-30",{"name":170,"class":102},"Huazhong University of Science and Technology",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":16,"minAge":177,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":21,"phases":180,"briefSummary":182,"conditions":183,"keywords":184,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":41},"100597339","phase-1-simultaneous-engagement-of-networks-for-alleviating-pain-senap-100597339","NCT07057206","Simultaneous Engagement of Networks for Alleviating Pain (SENAP)","Inclusion Criteria:\n\n* Age ≥ 22 years\n* Clinical diagnosis of a refractory chronic neuropathic pain syndrome suggestive of deafferentation or central pain. Non-limiting examples of these syndromes are:\n* post-traumatic pain syndromes (e.g. plexopathies, radiation-induced injury)\n* postsurgical pain syndromes (e.g. phantom limb pain, anesthesia dolorosa)\n* postherpetic neuralgia\n* Central pain syndromes (e.g. post-stroke pain, multiple sclerosis pain, post-radiation pain)\n* Greater than 6 months of chronic neuropathic pain\n* Average pain intensity over the past 30 days reported as 6 or greater on a 0-10 numeric rating scale (NRS)\n* Multidisciplinary pain consensus review that establishes\n* Pain is refractory to medical management\n* Pain that is refractory to or unlikely to be altered by less invasive treatment and\n* Pain distribution either does not permit attempts at relief by a targeted nerve block (e.g., post-stroke pain) or such blocks have provided \\\u003C25% relief.\n* Medication doses currently stable (no active titration or drug trials in progress) in the 30 days prior to baseline (immediately pre-surgical) study visit\n* Ability to speak \u002F read English\n* Capable of understanding and providing informed consent (verified if necessary by a standard tool such as the MacArthur Competency Assessment)\n* Women of childbearing age must be on regular use of an accepted contraceptive method(s).\n\nExclusion Criteria:\n\n* Pregnancy, breastfeeding, or unwilling to maintain regular use of contraceptives. Patients who become pregnant after enrollment may be excluded from the study if study procedures may cause risk to the fetus. Patients who become pregnant prior to the surgical implantation will be excluded from the study.\n* Aphasia severe enough to limit the consent process or communication between the investigators and the patient. Patients with mild or recovering aphasia may be considered candidates at the discretion of the PI.\n* Untreated or uncontrolled psychiatric illness (schizophrenia, bipolar disorder, obsessive-compulsive disorder), or personality disorders (e.g. borderline personality disorder) or other neuropsychiatric conditions that the evaluating clinician would recommend exclusion of the patient after neuropsychiatric evaluation.\n* History of seizure disorder and seizure within the last year. Participants with a remote history of epilepsy will need documentation from their neurologist for eligibility.\n* Suicide attempt within 12 months from baseline visit or imminent suicide risk in the judgment of study clinicians.\n* Modified Scale for Suicidal Ideation Score of greater than or equal to 21\n* History of diagnosed substance use disorder in the past 3 years. Benzodiazepines and\u002For opioids prescribed by a physician with use as directed do not count for this criterion. Cannabis\u002Fcannabinoid products will not be considered an exclusion if used under the auspices of a state-sponsored medical cannabis program.\n* Major medical comorbidities increasing the risk of surgery including uncontrolled hypertension, severe diabetes, major organ system failure, need for chronic anticoagulation other than aspirin, active infection, immunocompromised state, or malignancy with \\\u003C 5 years life expectancy.\n* Inability to temporarily stop anticoagulation therapy (approximately 3 weeks total) for surgery and after surgery. Patients taking these medications will need to discuss the need\u002Frisk of continuing these medications with their physicians and the PI or study personnel may contact the treating physician(s) as well to discuss the risks of anticoagulation \u002F antiaggregation therapy discontinuation.\n* MRI (done within one year of the baseline period) with significant abnormalities other than those associated with the neurological disorder causing chronic pain.\n* Implantable hardware not compatible with MRI or with the study or former metal worker that may pose risk from MRI.\n* Previous ablative intracranial surgery for the management of a central pain syndrome.\n* history of other neurosurgical procedures that may interfere with functioning of the device\n* Active, pending, or planned litigation or workman's compensation claim related to the pain\u002Finjury. Current receipt of disability benefits, without a dispute or litigation, is not an exclusion.\n* Requires ongoing or expected diathermy, electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) to treat a chronic condition\n* Allergies or known hypersensitivity to materials in the implanted system (i.e. titanium, polyurethane, silicone, polyetherimide, stainless steel).\n* Any other condition that, in the judgment of the PI or the Data Safety \\& Monitoring Board, significantly increases risk of receiving an implanted neurostimulator.\n* Those who require ongoing monitoring of a disease state by MRI.\n* Inability to target the somatocognitive action network or cingulate opercular network on fMRI","22 Years",{"count":179,"type":20},20,[181],"PHASE1","This trial is investigating the acceptability and efficacy of PFM-guided cortical stimulation for the treatment of central neuropathic pain.",[59,26],[59,185,186,26,187,188],"Post-Traumatic Pain","Post-Surgical Pain","Central Pain Syndrome","Chronic Neuropathic Pain","2026-01-05",{"date":191,"type":33},"2026-01-07",{"date":193,"type":20},"2026-07-01",{"date":195,"type":20},"2030-12",{"name":197,"class":102},"University of Minnesota",{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":21,"phases":207,"briefSummary":208,"conditions":209,"keywords":212,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":41},"100538425","clinical-trial-of-the-safety-and-efficacy-of-peripheral-nerve-stimulation-in-the-treatment-of-peripheral-neuropathic-pain-100538425","NCT06290661","Clinical Trial of the Safety and Efficacy of Peripheral Nerve Stimulation in the Treatment of Peripheral Neuropathic Pain.","Prospective, Multicentre, Randomised Withdrawal Design of a Clinical Trial Evaluating the Safety and Efficacy of a Percutaneous Peripheral Nerve Stimulation System for Patients With Peripheral Neuropathic Pain.","Inclusion criteria:\n\n* 18 years old and above, male or female\n* Diagnosed by trained clinical doctors as postherpetic neuralgia, which is an indication for peripheral nerve stimulation therapy;\n* Assess the damage or disease of the peripheral sensory system through the four questions of Douleur Neuropathy before surgery;\n* The subject has received conventional treatment but the efficacy is poor, or cannot tolerate the side effects of conventional treatment;\n* Visual analogue scale for pain within 24 hours before surgery ≥ 5;\n* The subjects are able to understand the purpose of this study, have sufficient compliance with the research treatment, and are willing to sign an informed consent form;\n\nExclusion criteria:\n\n* Subjects who need to receive both radio frequency modulation and intrathecal drug infusion treatment simultaneously;\n* Subjects who are known to have cardiac implants (pacemakers or defibrillators) or other implantable neural stimulators (spinal cord stimulators or deep brain stimulators, etc.);\n* Subjects with severe psychological and\u002For mental disorders and\u002For non therapeutic drug dependence;\n* Subjects expected to undergo MRI examination within 30 days after PNS implantation;\n* Expected to be discharged within 48 hours or less;\n* Target nerve damage or muscle defects in known pain areas;\n* Subjects who are known to be allergic to skin contact materials (tape or adhesive);\n* Allergy to anesthetics such as lidocaine;\n* Concomitant severe heart disease, liver disease, kidney disease, respiratory system disease, and coagulation dysfunction;\n* Pregnant women, lactating women, or women planning to have children within the next three months;\n* Subjects who have participated in any other clinical trial, or who may participate in any other trial after enrollment;\n* Other situations that the researcher deems unsuitable for participation in this clinical trial",{"count":206,"type":20},60,[54],"The goal of this clinical trial is to evaluate safety and efficacy of percutaneous peripheral nerve stimulation in patients with peripheral neuropathic pain. The main questions it aims to answer are:\n\n1. The efficacy of percutaneous peripheral nerve stimulation in patients with peripheral neuropathic pain\n2. The safety of percutaneous peripheral nerve stimulation in patients with peripheral neuropathic pain Participants are going to undergo procedure that implant peripheral nerve stimulation electrode produced by Jiangsu CED Medtech Co., Ltd. Then the subjects, whose VAS scores decrease more 30% than baseline level, are classified into two groups randomly. One of the group receiving active stimulation called trial group and another receiving placebo stimulation called control group. All subjects are required to make their own subjects' pain diary to record VSA score before and after implantation until at the end of follow-up. Also, participants are asked to report use of analgesic medications, number of awakenings and adverse events.\n\nResearchers will compare pain scores between the two groups to see if peripheral nerve stimulation is effective to patients with peripheral neuropathic pain.",[26,210,211],"Peripheral Neuropathic Pain","Trigeminal Neuralgia",[213,214],"Peripheral Nerve Stimulation","peripheral neuropathic pain","2025-07-22",{"date":217,"type":33},"2025-07-28",{"date":219,"type":33},"2023-02-09",{"date":221,"type":20},"2026-12-30",{"name":223,"class":102},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":231,"enrollmentInfo":232,"targetDuration":4,"studyType":21,"phases":234,"briefSummary":235,"conditions":236,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":41},"100592974","the-effectiveness-of-ultra-sound-guided-erector-spinae-block-with-betamethasone-for-management-of-truncal-chronic-post-herpetic-neuralgia-100592974","NCT07000409","The Effectiveness of Ultra-Sound Guided Erector Spinae Block With Betamethasone for Management of Truncal Chronic Post Herpetic Neuralgia.","The Effectiveness of Ultra-Sound Guided Erector Spinae Block With Betamethasone for Management of Truncal Chronic Post Herpetic Neuralgia, a Prospective Randomized Controlled Study.","Inclusion Criteria:\n\n* Patients age between 18 and 75.\n* Patients with American Society of Anesthesiologists (ASA) II and III status.\n* Patients diagnosed with truncal chronic post herpetic neuralgia( neuropathic pain persistent for more than 3 months from the onset of rash appearance )\n\nExclusion Criteria:\n\n* Patients unable to comprehend the informed consent.\n* Patients on long term opioid regimens.\n* Patients with impairment in hepatic (Alanine aminotransferase (ALT) \\>50 U\u002FL, and\u002For Aspartate aminotransferase (AST): \\>45 U\u002FL) or renal functions( creatinine level ≥1.5 mg\u002FdL)\n* Patients on anti-coagulation regimens.\n* Patients with coagulation abnormalities (i.e. international normalized ratio (INR) ≥1.5 and\u002For platelets ≤50000)\n* Local infection in the site of the block.\n* Patients with body mass index (BMI) \\> 35.","75 Years",{"count":233,"type":20},40,[54],"To investigate the effectiveness of ultra-Sound guided Erector spinae block (ESB) with Betamethasone as an adjuvant to standard medical protocol in the management of truncal chronic post herpetic neuralgia.",[26,137,237,238,239],"Ultrasound Guidance","Erector Spinae Plane Block","Betamethasone","2025-06-02",{"date":242,"type":33},"2025-06-05",{"date":244,"type":33},"2025-05-01",{"date":246,"type":20},"2025-12-30",{"name":248,"class":102},"Cairo University",{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":256,"targetDuration":4,"studyType":21,"phases":258,"briefSummary":259,"conditions":260,"keywords":261,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":269,"locationsCount":41},"100585025","esketamine-combined-pregabalin-and-duloxetine-for-postherpetic-neuralgia-100585025","NCT06896994","Esketamine Combined Pregabalin and Duloxetine for Postherpetic Neuralgia","Intravenous Infusion of Esketamine in Combination With Pregabalin and Duloxetine for Postherpetic Neuralgia","Inclusion Criteria:\n\n1. Ages more than 18 years;\n2. Pain present for more than 3 months after healing of a herpes zoster skin rash;\n3. Has an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0= no pain, 10= worst possible pain)；\n4. Failed to respond to or tolerate the effective dose of pregabalin monotherapy.\n\nExclusion Criteria:\n\n1. Obstructive sleep apnoea syndrome;\n2. Those who receive interventional treatments;\n3. A history of systemic immune diseases, organ transplantation, or cancers;\n4. A history of severe cardiopulmonary, hepatic or renal dysfunction;\n5. A history of schizophrenia, epilepsy, or myasthenia gravis, delirium;\n6. Currently using monoamine oxidase inhibitors (MAOIs);\n7. Having untreated angle-closure glaucoma;\n8. Those suffering from increased intracranial pressure；\n9. Comorbid hyperthyroidism or phaeochromocytoma;\n10. Suspected or confirmed history of drug abuse;\n11. Having contraindications to esketamine, pregabaline or duloxetine;\n12. Communication difficulties;\n13. Women who are preparing for pregnancy, in the pregnancy or lactation period.",{"count":257,"type":20},150,[54],"To assess the 1-week effects and safety of esketamine in combination with pregabalin and duloxetine to relieve pain in patients with postherpetic Neuralgia(PHN).",[26],[26,262],"esketamine","2025-04-24",{"date":265,"type":33},"2025-04-27",{"date":267,"type":33},"2025-04-01",{"date":75,"type":20},{"name":101,"class":102},{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":277,"targetDuration":4,"studyType":21,"phases":279,"briefSummary":280,"conditions":281,"keywords":282,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":288,"leadSponsor":289,"locationsCount":41},"100586347","esketamine-combined-with-prf-of-drg-for-postherpetic-neuralgia-100586347","NCT06914193","Esketamine Combined With PRF of DRG for Postherpetic Neuralgia","Intravenous Infusion of Esketamine in Combination With Pulsed Radiofrequency of Dorsal Root Ganglion for Postherpetic Neuralgia","Inclusion Criteria:\n\n1. Ages more than 18 years;\n2. Pain persisting for over three months following the onset of the herpes zoster skin rash;\n3. Lesions located in in the unilateral cervical, thoracic, and lumbosacral segments;\n4. Having an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0 = no pain, 10= worst possible pain)； Planned to perform CT-guided PRF treatment of the Dorsal root ganglion（DRG）\n\nExclusion Criteria:\n\n1. Obstructive sleep apnoea syndrome;\n2. Those who receive other more invasive treatments, such as radiofrequency thermocoagulation (RFT) of DRG.\n3. A history of systemic immune diseases, organ transplantation, or cancers;\n4. A history of severe cardiopulmonary, hepatic, renal dysfunction or coagulation function disorder;\n5. A history of schizophrenia, epilepsy, or myasthenia gravis, delirium;\n6. Comorbid hyperthyroidism or phaeochromocytoma;\n7. Recent history of drug abuse;\n8. Having contraindications to esketamine;\n9. Communication difficulties.\n10. Women who are preparing for pregnancy, in the pregnancy or lactation period.",{"count":278,"type":20},186,[54],"This trial's primary objective is to compare the analgesic efficacy of esketamine in combination with pulsed radiofrequency (PRF) of dorsal root ganglion(DRG) against that of PRF monotherapy in patients with postherpetic neuralgia(PHN).",[26],[26,283],"Esketamine","2025-04-05",{"date":286,"type":33},"2025-04-09",{"date":267,"type":20},{"date":124,"type":20},{"name":101,"class":102},{"id":291,"slug":292,"hasResults":11,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":11,"sex":16,"minAge":297,"maxAge":110,"enrollmentInfo":298,"targetDuration":4,"studyType":21,"phases":300,"briefSummary":301,"conditions":302,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":41},"100548421","the-treatment-of-postherpetic-neuralgia-in-the-head-and-face-with-superficial-needling-combined-with-electroacupuncture-100548421","NCT06420778","The Treatment of Postherpetic Neuralgia in the Head and Face With Superficial Needling Combined With Electroacupuncture","A Randomized Controlled Study on the Treatment of Postherpetic Neuralgia in the Head and Face With Superficial Needling Combined With Electroacupuncture","Inclusion Criteria:\n\nMeet the diagnostic criteria in the 2016 Chinese Expert Consensus on the Diagnosis and Treatment of Postherpetic Neuralgia; Age 50-80 years (including telangiectasia), gender is not limited; Have a history of herpes zoster on the head and face, and the lesions on the head and face have been healed and subsided, and the symptoms of neuralgia lasted ≥1 month after lesions were healed, with baseline scores of ≥4 on the Facial Pain Profile, and abnormal sensation of the skin around the lesions, pain sensitivity; Be conscious and have a clear sense of pain and discriminative ability; Sign the informed consent to participate in this study voluntarily. Only those who satisfy the above 5 items at the same time can be included in this study.\n\nExclusion Criteria:\n\nthose who did not meet the above diagnostic criteria; herpes zoster occurring in the perineum, or special types such as visceral herpes zoster, meningeal herpes zoster, and generalized herpes zoster; those who were taking oral pregabalin at a dose of less than 0.2 g or more than 0.6 g per day before inclusion to relieve analgesia; those who had a serious adverse reaction to pregabalin, were allergic to acupuncture, or belonged to patients who were within the range of contraindications to electro-acupuncture; Combined with severe cardiac, hepatic, renal damage, epilepsy, head injury, or cognitive dysfunction, aphasia, psychiatric disorders, and other major diseases, who are unable to cooperate with the treatment; Combined with poorly controlled hypertension and diabetes mellitus patients; Pregnant or breastfeeding patients;8.Patients who are currently participating in other studies, and who have been enrolled in other clinical trials within the last 3 months. Anyone who meets any of these criteria will be excluded.","50 Years",{"count":299,"type":20},124,[54],"Based on the inclusion and exclusion criteria, patients with head and face PHN who met the requirements were selected as trial subjects, and the efficacy was clarified in a randomized controlled design trial. The visual analog score VAS was used as the primary evaluation index, and the depression self-assessment scale score , Hamilton depression scale, Pittsburgh sleep quality index scale, and quality of life evaluation scale (SF-36) were used as the secondary evaluation indexes, and oral pregabalin was used as the control group, and the subjects in the pregabalin and the plexus superficial stabbing combined with electroacupuncture groups were observed respectively at the time of Before treatment, immediately after the first treatment, after 2 days of treatment, after 2 weeks of treatment, after 4 weeks of treatment, after 1 month of follow-up after the end of treatment and after 2 months of follow-up after the end of treatment.",[26,303,304],"Electroacupuncture","Infrared Thermography","2025-04-02",{"date":307,"type":33},"2025-04-06",{"date":309,"type":33},"2024-07-12",{"date":311,"type":20},"2025-12-31",{"name":313,"class":314},"Zhejiang Chinese Medical University","OTHER_GOV"]